Home > Search Results
  • Added to PubMed Health

    clear
    • Custom range...

Treats irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).

UsesSide effectsLatest evidence reviewsResearch summaries for consumersBrand names

Results: 8

Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis

BACKGROUND: Treatment options for constipation-predominant irritable bowel syndrome (IBS-C) are limited. While linaclotide improved IBS-C symptoms in randomized controlled trials (RCTs), results vary among studies and the magnitude of benefit is unclear.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2014

Linaclotide: a new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation

INTRODUCTION: Linaclotide is the first member of a novel class of drugs to be extensively evaluated for the treatment of chronic constipation (CC) and irritable bowel syndrome with constipation (IBS-C).

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis

BACKGROUND & AIMS: Linaclotide is a minimally absorbed, 14-amino acid peptide used to treat patients with irritable bowel syndrome with constipation (IBS-C) or chronic constipation (CC). We performed a meta-analysis to determine the efficacy of linaclotide, compared with placebo, for patients with IBS-C or CC.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Treatments for Constipation: A Review of Systematic Reviews [Internet]

Constipation has many definitions and is often described differently depending on the population queried. Physicians may define constipation as a reduction in the frequency of bowel movements to fewer than three times per week while patients identify more with the symptoms associated with constipation such as difficulty passing stool, hard stool consistency, feelings of abdominal cramping, and feelings of incomplete stool passage. Causes of constipation may be primary (idiopathic) or secondary to other factors such as diet, medication, or medical conditions. Constipation can affect anyone as a minor annoyance but up to a quarter of the population experiences it chronically or severely. It can substantially affect quality of life and be debilitating. It is estimated that between 2% to 27% of the population are affected depending upon the definition of constipation used.

Rapid Response Report: Summary with Critical Appraisal - Canadian Agency for Drugs and Technologies in Health.

Version: November 17, 2014
Show search results within this document

Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report [Internet]

To compare the effectiveness and adverse event profiles of amylin agonists, DPP-4 inhibitors, incretin mimetics, TZDs, and certain combination products for people with type 2 diabetes and for people with type 1 diabetes for pramlintide only.

Drug Class Reviews - Oregon Health & Science University.

Version: February 2011
Show search results within this document

Drug Class Review: Newer Drugs for the Treatment of Diabetes Mellitus: Final Report [Internet]

Diabetes mellitus (diabetes) is a chronic and insidious disease affecting more than 20 million Americans, approximately 7% of the population. Within the last 1 to 2 years, three new antihyperglycemic agents have been approved: pramlintide, exenatide, and sitagliptin. These agents offer mechanisms of glycemic control beyond that of "traditional" oral agents and insulin by targeting alternate gluco-regulatory receptors and hormones such as amylin, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and dipeptidyl peptidase-4 (DPP-4). The purpose of this review was to compare the effectiveness and harms of newer diabetes medications for persons with diabetes mellitus.

Drug Class Reviews - Oregon Health & Science University.

Version: August 2008
Show search results within this document

Wireless Motility Capsule Versus Other Diagnostic Technologies for Evaluating Gastroparesis and Constipation: A Comparative Effectiveness Review [Internet]

To systematically review the evidence comparing wireless motility capsule (WMC) with other diagnostic tests used for the evaluation of gastroparesis and slow-transit constipation, in terms of diagnostic accuracy, accuracy of motility assessment, effect on treatment decisions, effect on patient-centered outcomes, harms, and effect on resource utilization.

Comparative Effectiveness Reviews - Agency for Healthcare Research and Quality (US).

Version: May 2013
Show search results within this document

Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis

The review found that laxatives, prucalopride, lubiprostone and linaclotide were all more effective than placebo for short-term treatment of chronic idiopathic constipation, but were associated with a greater frequency of diarrhoea. The authors' appropriate conclusions reflect the evidence base and are likely to be reliable.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2011

Systematic Reviews in PubMed

See all (15)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...